1. Home
  2. CAF vs ALLO Comparison

CAF vs ALLO Comparison

Compare CAF & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley China A Share Fund Inc.

CAF

Morgan Stanley China A Share Fund Inc.

HOLD

Current Price

$17.24

Market Cap

276.0M

Sector

Finance

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.53

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAF
ALLO
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
276.0M
252.9M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
CAF
ALLO
Price
$17.24
$1.53
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$8.67
AVG Volume (30 Days)
63.6K
2.5M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
1.02%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.63
$0.86
52 Week High
$14.38
$3.78

Technical Indicators

Market Signals
Indicator
CAF
ALLO
Relative Strength Index (RSI) 67.18 62.29
Support Level $17.05 $1.41
Resistance Level $17.44 $1.52
Average True Range (ATR) 0.18 0.10
MACD 0.17 0.01
Stochastic Oscillator 88.65 86.96

Price Performance

Historical Comparison
CAF
ALLO

About CAF Morgan Stanley China A Share Fund Inc.

Morgan Stanley China A Share Fund Inc is the United States based non-diversified, closed-end management investment company. Its investment objective is to seek capital growth by investing a majority of its assets in A-shares of Chinese companies listed on the Shanghai and Shenzhen Stock Exchanges. Its portfolio of investments consists of investment in different sectors such as the aerospace and defense, banks, automobiles, household durables, media, pharmaceuticals, software and other sectors.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: